Brian F. Chapin, M.D. on the Uptake of PSMA PET in Prostate Imaging


The approval of Blue Earth Diagnostics' Posluma (flotufolastat F 18) is a significant step forward for PSMA PET imaging, but will it actually help improve patient outcomes?

This content originally appeared on our sister site, Urology Times.

Prostate cancer imaging is having its moment in the spotlight, with numerous advances in imaging agents for positron emission tomography slated to help improve diagnostics in a disease that's rife with recurrence.

The most recent news comes from Blue Earth Diagnostics, whose radioactive imaging agent Posluma (flotufolastat F 18) was recently approved in May 2023 for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

While improved imaging will certainly move the needle on diagnosis, it's yet to be seen how this will ultimately impact patient outcomes.

In an interview with our sister site, Urology Times, Brian F. Chapin, M.D., associate professor of urology at the University of Texas MD Anderson Cancer Center in Houston, spoke about the potential impact of PSMA PET and some of the challenges the clinical community is facing in the wake of these advances.

Click here for more of the latest research on prostate imaging.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.